Pliant Therapeutics, Inc. (PLRX) NASDAQ
1.16
-0.04(-3.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.16
-0.04(-3.33%)
Currency In USD
| Previous Close | 1.2 |
| Open | 1.2 |
| Day High | 1.22 |
| Day Low | 1.15 |
| 52-Week High | 1.95 |
| 52-Week Low | 1.09 |
| Volume | 961,310 |
| Average Volume | 498,647 |
| Market Cap | 71.83M |
| PE | -0.63 |
| EPS | -1.83 |
| Moving Average 50 Days | 1.25 |
| Moving Average 200 Days | 1.39 |
| Change | -0.04 |
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
GlobeNewswire Inc.
Feb 23, 2026 1:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participati
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
GlobeNewswire Inc.
Dec 04, 2025 12:30 PM GMT
One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development o
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Dec 01, 2025 1:30 PM GMT
SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in th